BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Holding BMRN?
Track your performance easily

BioMarin Pharmaceutical (BMRN) Ownership - Who Owns BioMarin Pharmaceutical?

1,984 Followers

BioMarin Pharmaceutical (BMRN) Ownership Overview

0.96%37.62%12.45%23.12%25.85%
12.45% Other Institutional Investors
23.12% ETFs
25.85% Public Companies and Individual Investors
The ownership structure of BioMarin Pharmaceutical (BMRN) stock is a mix of institutional, retail, and individual investors. Approximately 73.19% of the company’s stock is owned by Institutional Investors, 0.96% is owned by Insiders, and 25.85% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Mar 07, 2024
Henry Fuchs
President, Worldwide R&d
xxxxxxxxxxxxx
$3010346
Mar 07, 2024
xxxxxxxxxxxxx
$172220
Feb 29, 2024
xxxxxxxxxxxxx
$90350
Dec 12, 2023
xxxxxxxxxxxxx
$856

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
18,790,085Institution9.86%1,260,251,001
18,398,819Institution9.65%1,234,008,790
16,788,800Institution8.81%1,126,024,816
13,930,493Institution7.31%934,318,166
13,178,282Institution6.91%883,867,374
10,543,625Institution5.53%707,160,929
7,070,808Institution3.71%474,239,093
7,063,564Institution3.71%473,753,237
5,486,780Institution2.88%367,998,335
5,189,752Institution2.72%348,076,667

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
16,788,800Institution8.81%1,126,024,816
10,543,625Institution5.53%707,160,929
7,070,808Institution3.71%474,239,093
5,486,780Institution2.88%367,998,335
4,971,836Institution2.61%333,461,041
4,610,520Institution2.42%309,227,576
3,552,206Institution1.86%238,246,456
1,973,809Institution1.04%132,383,370
1,892,412Institution0.99%126,924,073
870,536Institution0.46%58,386,850

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
6,039,517Institution3.17%424,517,650
6,013,698Institution3.16%402,556,944
4,031,904Institution2.12%283,402,532
2,846,405Institution1.49%200,073,807
2,406,830Institution1.26%169,176,081
2,248,880Institution1.18%150,540,027
1,525,348Institution0.80%102,305,090
1,340,721Institution0.70%94,239,279
1,323,259Institution0.69%88,750,981
863,786Institution0.45%57,934,127

FAQ

Who Owns BioMarin Pharmaceutical (BMRN)?
According to the latest TipRanks data, approximately 12.45% of the company's stock is held by institutional investors, 0.96% is held by insiders, and 25.85% is held by retail investors.
    What percentage of BioMarin Pharmaceutical (BMRN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 12.45% of BioMarin Pharmaceutical (BMRN) stock is held by institutional investors.
      What percentage of BioMarin Pharmaceutical (BMRN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 25.85% of BioMarin Pharmaceutical (BMRN) stock is held by retail investors.
        Who owns the most shares of BioMarin Pharmaceutical (BMRN)?
        Theofanis Kolokotrones owns the most shares of BioMarin Pharmaceutical (BMRN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis